Rhumbline Advisers Purchases 7,143 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Rhumbline Advisers lifted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 12.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,535 shares of the company’s stock after buying an additional 7,143 shares during the quarter. Rhumbline Advisers owned about 0.11% of Kymera Therapeutics worth $1,926,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quest Partners LLC bought a new position in Kymera Therapeutics during the fourth quarter worth $78,000. Comerica Bank boosted its position in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the period. Ameritas Investment Partners Inc. boosted its position in Kymera Therapeutics by 7.8% during the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after purchasing an additional 295 shares during the period. Virtu Financial LLC bought a new position in Kymera Therapeutics during the first quarter worth $207,000. Finally, Keudell Morrison Wealth Management bought a new position in Kymera Therapeutics during the first quarter worth $266,000.

Insider Transactions at Kymera Therapeutics

In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 495,605 shares of company stock worth $19,303,364. Insiders own 15.82% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Leerink Partners reissued an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Wells Fargo & Company boosted their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research note on Monday, August 12th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target for the company in a research note on Monday, August 26th. Finally, Morgan Stanley boosted their price target on Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.67.

Kymera Therapeutics Trading Up 1.6 %

NASDAQ:KYMR opened at $49.79 on Friday. The stock has a market cap of $3.06 billion, a P/E ratio of -19.84 and a beta of 2.22. The stock’s 50-day moving average is $45.28 and its 200-day moving average is $39.09. Kymera Therapeutics, Inc. has a 1-year low of $9.60 and a 1-year high of $50.69.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10. The company had revenue of $25.60 million for the quarter, compared to analysts’ expectations of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The business’s quarterly revenue was up 55.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.67) earnings per share. As a group, equities analysts forecast that Kymera Therapeutics, Inc. will post -2.87 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.